Tel Aviv, Israel / Vancouver, Canada, July 17, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the “company”), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, today announced that it has issued 17,899 common shares in the capital of the Company (“Shares”)…

Source

Previous articlePsychedelic Bulletin #141: Terran’s 4-OH-DiPT Prodrug Patent App.; Generic Ketamine Appears Effective for TRD; VA/DoD Guideline Reviews Psychedelics
Next articlePharmaTher Announces Positive Research Results for PharmaPatch™ with N,N-dimethyltryptamine (DMT) and Strategic Investment into Sairiyo Therapeutics